REG - Avacta Group PLC - Avacta to present clinical data at ESMO Congress

AvactaAnnouncement

09/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240909:nRSI3279Da&default-theme=true

RNS Number : 3279D  Avacta Group PLC  09 September 2024

 

 

 
9 September 2024

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Avacta to present updated clinical data on AVA6000 at the European Society for
Medical Oncology (ESMO) Congress

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted cancer treatments and powerful diagnostics, today announces that the
company will present updated data from the Phase 1a trial of AVA6000 at the
2024 European Society for Medical Oncology (ESMO) Congress, in Barcelona,
Spain from 13-17 September 2024.

The poster presentation will be based on an updated data cut from the Phase 1a
trial of AVA6000 in patients with Fibroblast Activation Protein (FAP)-positive
solid tumours. AVA6000 is a peptide drug conjugate consisting of doxorubicin
conjugated with a peptide moiety that is specifically cleaved by FAP in the
tumour microenvironment.

Abstract details are listed below and available online on the ESMO website.

 

Title: A Phase I trial of AVA6000, a Fibroblast Activation Protein
(FAP)-released, tumour microenvironment (TME)-targeted doxorubicin peptide
drug conjugate in patients with FAP-positive solid tumours

Session Title: Developmental therapeutics

Session Date and Time: Saturday, September 14, 2024, 9AM CEST time.

Location: Fira Barcelona Gran Via Av. Joan Carles, Barcelona, Spain

Abstract Presentation Number: 646P

First Author: Professor Chris Twelves, University of Leeds

 

 

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                      Tel: +44 (0) 1904 21 7070

 Christina Coughlin, CEO                               www.avacta.com (http://www.avacta.com/)

 Michael Vinegrad, Group Communications

 Director

 Peel Hunt (Nomad and Broker)

 James Steel / Chris Golden / Patrick Birkholm         www.peelhunt.com (http://www.peelhunt.com/)

 ICR Consilium

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji   avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 

 

 

About Avacta Group plc - www.avacta.com (http://www.avacta.com/)

 

Avacta Group is a UK-based life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and diagnostics.

 

Avacta Therapeutics: a clinical stage oncology biotech division harnessing
proprietary therapeutic platforms to develop novel, highly targeted cancer
drugs.

 

Avacta Diagnostics focuses on supporting healthcare professionals and
broadening access to diagnostics.

 

Avacta has two proprietary platforms, pre|CISION™ and Affimer(®).

 

The pre|CISION™ platform is a highly specific substrate for fibroblast
activation protein (FAP) which is upregulated in most solid tumours compared
with healthy tissues. The pre|CISION™ platform harnesses this tumour
specific protease to activate pre|CISION™ peptide drug conjugates and
pre|CISION™ antibody/Affimer® drug conjugates in the tumour
microenvironment, reducing systemic exposure and toxicity, allowing dosing to
be optimised to deliver the best outcomes for patients.

 

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of
doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and
tolerability in clinical trials to date compared with standard doxorubicin and
preliminary signs of clinical activity in multiple patients.

 

 

To register for news alerts by email go
to www.avacta.com/investor-news-email-alerts
(http://www.avacta.com/investor-news-email-alerts)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESFLFIDAIITIIS